Catalyst Pharmaceutical Partners (CPRX) 2.97 $CPRX
i"Catalyst Pharmaceuticals elects David J. Caponera as VP of patient advocacy and reimbursement
M2 - Wed Oct 29, 5:05AM CDT
Biopharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) revealed on Tuesday the election of David J. Caponera to the newly created position of vice president, patient advocacy and reimbursement.
CPRX: 2.97 (+0.23)
Catalyst Pharmaceuticals Appoints David J. Caponera as Vice President Patient Advocacy and Reimbursement
GlobeNewswire - Tue Oct 28, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, announced the appointment of David J. Caponera to the newly created position, vice president, patient advocacy and reimbursement, effective immediately. Mr. Caponera will report to David D. Muth, executive vice president, corporate development.
CPRX: 2.97 (+0.23)
Catalyst Pharmaceuticals to Present Firdapse Phase 3 Trial Results at the 61st Annual Meeting of the American Association of Neuromuscular and Electrodiagnostic Medicine
GlobeNewswire - Mon Oct 27, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that safety and efficacy results from its Firdapse(TM) Phase 3 trial will be presented as part of an Industry Forum at the 61 Annual Meeting of the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) being held at the Savannah, Georgia International Trade and Convention Center, Oct. 29-Nov. 1. The Catalyst-sponsored forum will occur on Friday, Oct, 31 at 12:00 pm EDT and include presentations on the diagnosis and treatment of LEMS and Congenital Myasthenic Syndrome (CMS) by several Firdapse Phase 3 clinical study investigators and the Firdapse Expanded Access Program (EAP) by Catalyst's chief medical officer. Catalyst will also be exhibiting at booth #515 during the AANEM. The presentation materials will be posted at www.catalystpharma.com in the Investors section under Events & Presentations.
CPRX: 2.97 (+0.23)
Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners
PR Newswire - Fri Oct 17, 8:30AM CDT
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), XOMA Corporation (NASDAQ: XOMA), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 16, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 16,117.24, down 0.15% and the NASDAQ Composite closed at 4,217.39, up 0.05%. The S&P 500 finished the session 0.01% higher at 1,862.76. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 696.64, down 0.50%, whereas the index has advanced 8.46% on YTD basis. Register for your complimentary reports on these five stocks at:
CPRX: 2.97 (+0.23), NPSP: 27.40 (-1.06), MNTA: 10.91 (-0.08), ARNA: 4.36 (-0.09), XOMA: 4.29 (-0.28)
Catalyst Pharmaceuticals to Present Top-Line Safety and Efficacy Results From Phase 3 Firdapse Trial at 139th Annual Meeting of the American Neurological Association
GlobeNewswire - Wed Oct 08, 7:35AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals) a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that Douglas Winship, Vice President of Regulatory Operations, will present top-line safety and efficacy results from Catalyst's Phase 3 Firdapsetrial at the 139 Annual Meeting of the American Neurological Association being held at The Baltimore Waterfront Marriott, October 12-14. The presentation, entitled, "A Phase 3 Trial of Firdapse(TM) Tablets in Lambert-Eaton Myasthenic Syndrome," to be delivered at the Neuromuscular Disease Special Interest Symposia, is scheduled for Sunday, October 12 at 5:20 pm (EDT). In addition, the Company will have a poster presentation (Poster #S737WIP) at the conference from 5:30 to 7:00 pm EDT. The presentation materials will be posted at www.catalystpharma.com in the Investors section under Events & Presentations.
CPRX: 2.97 (+0.23)
ITE, ESEA, CPRX Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Wed Oct 08, 3:34AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of SPDR Barclays Capital Intermediate Term Treas ETF (NYSE:ITE), Euroseas Ltd (NASDAQ:ESEA), Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ESEA: 1.05 (+0.05), CPRX: 2.97 (+0.23), ITE: 59.96 (+0.03)
Biotech Stock Mailbag: Seattle Genetics, Achillion, Catalyst Pharma
at The Street - Fri Oct 03, 8:41AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
JNJ: 107.78 (+0.74), SGEN: 36.67 (+1.42), CPRX: 2.97 (+0.23), ACHN: 11.75 (-0.20), SNSS: 1.70 (unch), BMY: 58.19 (-0.79)
Catalyst Pharmaceuticals to Present at 13th Annual BIO Investor Forum
GlobeNewswire - Thu Oct 02, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals) a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will present at the 13 Annual BIO Investor Forum being held at The Palace Hotel in San Francisco, California, October 7-8. The presentation is scheduled for Tuesday, October 7 at 2:00 pm (PDT). The presentation materials will be posted at www.catalystpharma.com in the Investors section under Events & Presentations.
CPRX: 2.97 (+0.23)
Why Catalyst Pharmaceutical Partners (CPRX) Stock Is Spiking Today
at The Street - Tue Sep 30, 2:09PM CDT
Catalyst Pharmaceutical Partners (CPRX) shares rose after ROTH Capital raised the company's price target to $6 from $5 and reiterated its 'buy' rating.
CPRX: 2.97 (+0.23)
Catalyst Pharma Closer to Unconscionable Price Hike for Rare-Disease Drug
at The Street - Tue Sep 30, 6:20AM CDT
For the zero work done by Catalyst, LEMS patients will pay as much as $80,000 for the exact same drug they use now for a fraction of the cost.
MNK: 92.18 (-0.65), BMRN: 82.50 (+0.14), CPRX: 2.97 (+0.23), RTRX: 9.68 (+0.15)
Market Maker Surveillance Report. DWA, LOOK, RADA, AMAG, CPRX, OSN, Winning Stocks With Lowest Price Friction For Monday, September 29th 2014
M2 - Tue Sep 30, 3:57AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 5089 companies with "abnormal" market making, 1819 companies with positive Friction Factors and 3032 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Monday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Dreamworks Animation Skg Inc (NASDAQ
WA), Looksmart Ltd (NASDAQ:LOOK), Rada Electronic Industries Ltd (NASDAQ:RADA), AMAG Pharmaceuticals Inc (NASDAQ:AMAG), Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX), Ossen Innovation Co Ltd (NASDAQ:OSN). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
OSN: 0.91 (+0.02), RADA: 2.53 (+0.10), CPRX: 2.97 (+0.23), LOOK: 1.44 (-0.02), AMAG: 33.01 (-0.95), DWA: 22.28 (+0.25)
Catalyst Pharmaceuticals Announces Positive Top-Line Phase 3 Data From Pivotal Firdapse Clinical Trial in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
GlobeNewswire - Mon Sep 29, 3:03PM CDT
Treatment with Firdapse achieved statistical significance for both co-primary clinical endpoints
CPRX: 2.97 (+0.23)
DON, EEB, PRFZ, CPRX, RGI, DVR Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Sep 10, 3:54AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Donner Metals Ltd (NYSE ON), Guggenheim BRIC ETF (NYSE:EEB), PowerShares FTSE RAFI US 1500 Small-Mid Portfolio (NASDAQ
RFZ), Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX), Reco International Group Inc (NYSE:RGI), Cal Dive International Inc (NYSE VR) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
DON: 81.83 (+0.85), RGI: 87.96 (+0.91), DVR: 0.14 (-0.08), CPRX: 2.97 (+0.23), RGI.VN: 0.015 (unch), PRFZ: 99.11 (+1.57), EEB: 34.47 (+0.32)
Opium (Opioid) Addiction - Pipeline Review, H2 2014 - 19 Drug Profiles from 13 Companies
M2 - Tue Sep 09, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/76t4hq/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alkermes Plc - Nanotherapeutics, Inc. - Acura Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - INSYS Therapeutics, Inc. - Camurus AB - Omeros Corporation - D&A Pharma SAS - Reckitt Benckiser Pharmaceutical, Inc. - AllTranz, Inc. - Relmada Therapeutics, Inc. - Celtic Pharmaceutical Holdings L.P. - Foresee Pharmaceuticals, LLC Drug Profiles - TA-CD - buprenorphine hydrochloride - RBP-6300 - Cannabidiol - OMS-405 - MAL - samidorphan - (buprenorphine hydrochloride naloxone hydrochloride) - CPP-115 - OMS-527 - buprenorphine hydrochloride ER - Vaccine for Opium Addiction - Cannabidiol - FP-004 - methadone IR - buprenorphine hydrochloride - Synthetic Peptides to Activate DOR and MOR and Inhibit MRP-1 for Oncology and Morphine Addiction - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - naltrexone For more information visit http://www.researchandmarkets.com/research/76...ium_opioid
INSY: 40.67 (-1.32), CPRX: 2.97 (+0.23), ALKS: 50.55 (-0.74), ACUR: 0.61 (-0.02), OMER: 16.57 (unch)
Biotech Equities Technical Review -- Celldex Therapeutics, Synthetic Biologics, Geron, Catalyst Pharmaceutical Partners, and NPS Pharmaceuticals
PR Newswire - Mon Sep 08, 8:15AM CDT
On Friday, September 05, 2014, the NASDAQ Composite ended at 4,582.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.40% higher at 17,137.36, and the S&P 500 closed at 2,007.71, up 0.50%. The gains were broad based as all the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 741.23, up 0.57%, and the index has advanced 5.89% in the last one month. Investor-Edge has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Synthetic Biologics Inc. (NYSE MKT: SYN), Geron Corporation (NASDAQ: GERN), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX), and NPS Pharmaceuticals Inc. (NASDAQ: NPSP). Free research on these five companies can be accessed at:
SYN: 1.51 (-0.06), CPRX: 2.97 (+0.23), GERN: 2.23 (+0.02), CLDX: 16.75 (-0.27), NPSP: 27.40 (-1.06)
Catalyst Pharmaceutical (CPRX) Jumps: Stock Up 9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 7:51AM CDT
Catalyst Pharmaceutical Partners Inc. (CPRX) was a big mover last session, as its shares rose nearly 9% on the day.
LCI: 56.72 (+0.83), ENDP: 66.92 (+0.63), CPRX: 2.97 (+0.23), HPTX: 24.30 (-0.13)
Catalyst Pharmaceuticals hires David D. Muth as EVP of Corporate Development
M2 - Fri Sep 05, 6:32AM CDT
Biopharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) reported on Thursday the addition of David D. Muth as executive vice president of its Corporate Development.
CPRX: 2.97 (+0.23)
Catalyst Pharmaceuticals Appoints David D. Muth as Executive Vice President, Corporate Development
GlobeNewswire - Thu Sep 04, 7:26AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the appointment of David D. Muth to the newly created position, Executive Vice President, Corporate Development. Mr. Muth will report to Patrick McEnany, Chairman, President and Chief Executive Officer of Catalyst. As Executive Vice President, Corporate Development, Mr. Muth will be responsible for all of Catalyst's corporate development activities and will work closely with the other members of the Catalyst team in preparing a commercialization strategy for Firdapse(TM).
CPRX: 2.97 (+0.23)
Catalyst Pharmaceutical Partners to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
GlobeNewswire - Wed Sep 03, 7:08AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will be presenting at Rodman & Renshaw's 16 Annual Global Investment Conference, which is being held on September 8-10, 2014 at The Palace Hotel in New York, NY.
CPRX: 2.97 (+0.23)
i"Catalyst Pharmaceuticals elects David J. Caponera as VP of patient advocacy and reimbursement
M2 - Wed Oct 29, 5:05AM CDT
Biopharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) revealed on Tuesday the election of David J. Caponera to the newly created position of vice president, patient advocacy and reimbursement.
CPRX: 2.97 (+0.23)
Catalyst Pharmaceuticals Appoints David J. Caponera as Vice President Patient Advocacy and Reimbursement
GlobeNewswire - Tue Oct 28, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, announced the appointment of David J. Caponera to the newly created position, vice president, patient advocacy and reimbursement, effective immediately. Mr. Caponera will report to David D. Muth, executive vice president, corporate development.
CPRX: 2.97 (+0.23)
Catalyst Pharmaceuticals to Present Firdapse Phase 3 Trial Results at the 61st Annual Meeting of the American Association of Neuromuscular and Electrodiagnostic Medicine
GlobeNewswire - Mon Oct 27, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that safety and efficacy results from its Firdapse(TM) Phase 3 trial will be presented as part of an Industry Forum at the 61 Annual Meeting of the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) being held at the Savannah, Georgia International Trade and Convention Center, Oct. 29-Nov. 1. The Catalyst-sponsored forum will occur on Friday, Oct, 31 at 12:00 pm EDT and include presentations on the diagnosis and treatment of LEMS and Congenital Myasthenic Syndrome (CMS) by several Firdapse Phase 3 clinical study investigators and the Firdapse Expanded Access Program (EAP) by Catalyst's chief medical officer. Catalyst will also be exhibiting at booth #515 during the AANEM. The presentation materials will be posted at www.catalystpharma.com in the Investors section under Events & Presentations.
CPRX: 2.97 (+0.23)
Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners
PR Newswire - Fri Oct 17, 8:30AM CDT
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), XOMA Corporation (NASDAQ: XOMA), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 16, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 16,117.24, down 0.15% and the NASDAQ Composite closed at 4,217.39, up 0.05%. The S&P 500 finished the session 0.01% higher at 1,862.76. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 696.64, down 0.50%, whereas the index has advanced 8.46% on YTD basis. Register for your complimentary reports on these five stocks at:
CPRX: 2.97 (+0.23), NPSP: 27.40 (-1.06), MNTA: 10.91 (-0.08), ARNA: 4.36 (-0.09), XOMA: 4.29 (-0.28)
Catalyst Pharmaceuticals to Present Top-Line Safety and Efficacy Results From Phase 3 Firdapse Trial at 139th Annual Meeting of the American Neurological Association
GlobeNewswire - Wed Oct 08, 7:35AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals) a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that Douglas Winship, Vice President of Regulatory Operations, will present top-line safety and efficacy results from Catalyst's Phase 3 Firdapsetrial at the 139 Annual Meeting of the American Neurological Association being held at The Baltimore Waterfront Marriott, October 12-14. The presentation, entitled, "A Phase 3 Trial of Firdapse(TM) Tablets in Lambert-Eaton Myasthenic Syndrome," to be delivered at the Neuromuscular Disease Special Interest Symposia, is scheduled for Sunday, October 12 at 5:20 pm (EDT). In addition, the Company will have a poster presentation (Poster #S737WIP) at the conference from 5:30 to 7:00 pm EDT. The presentation materials will be posted at www.catalystpharma.com in the Investors section under Events & Presentations.
CPRX: 2.97 (+0.23)
ITE, ESEA, CPRX Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Wed Oct 08, 3:34AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of SPDR Barclays Capital Intermediate Term Treas ETF (NYSE:ITE), Euroseas Ltd (NASDAQ:ESEA), Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ESEA: 1.05 (+0.05), CPRX: 2.97 (+0.23), ITE: 59.96 (+0.03)
Biotech Stock Mailbag: Seattle Genetics, Achillion, Catalyst Pharma
at The Street - Fri Oct 03, 8:41AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
JNJ: 107.78 (+0.74), SGEN: 36.67 (+1.42), CPRX: 2.97 (+0.23), ACHN: 11.75 (-0.20), SNSS: 1.70 (unch), BMY: 58.19 (-0.79)
Catalyst Pharmaceuticals to Present at 13th Annual BIO Investor Forum
GlobeNewswire - Thu Oct 02, 7:03AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals) a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will present at the 13 Annual BIO Investor Forum being held at The Palace Hotel in San Francisco, California, October 7-8. The presentation is scheduled for Tuesday, October 7 at 2:00 pm (PDT). The presentation materials will be posted at www.catalystpharma.com in the Investors section under Events & Presentations.
CPRX: 2.97 (+0.23)
Why Catalyst Pharmaceutical Partners (CPRX) Stock Is Spiking Today
at The Street - Tue Sep 30, 2:09PM CDT
Catalyst Pharmaceutical Partners (CPRX) shares rose after ROTH Capital raised the company's price target to $6 from $5 and reiterated its 'buy' rating.
CPRX: 2.97 (+0.23)
Catalyst Pharma Closer to Unconscionable Price Hike for Rare-Disease Drug
at The Street - Tue Sep 30, 6:20AM CDT
For the zero work done by Catalyst, LEMS patients will pay as much as $80,000 for the exact same drug they use now for a fraction of the cost.
MNK: 92.18 (-0.65), BMRN: 82.50 (+0.14), CPRX: 2.97 (+0.23), RTRX: 9.68 (+0.15)
Market Maker Surveillance Report. DWA, LOOK, RADA, AMAG, CPRX, OSN, Winning Stocks With Lowest Price Friction For Monday, September 29th 2014
M2 - Tue Sep 30, 3:57AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 5089 companies with "abnormal" market making, 1819 companies with positive Friction Factors and 3032 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Monday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Dreamworks Animation Skg Inc (NASDAQ
WA), Looksmart Ltd (NASDAQ:LOOK), Rada Electronic Industries Ltd (NASDAQ:RADA), AMAG Pharmaceuticals Inc (NASDAQ:AMAG), Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX), Ossen Innovation Co Ltd (NASDAQ:OSN). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . OSN: 0.91 (+0.02), RADA: 2.53 (+0.10), CPRX: 2.97 (+0.23), LOOK: 1.44 (-0.02), AMAG: 33.01 (-0.95), DWA: 22.28 (+0.25)
Catalyst Pharmaceuticals Announces Positive Top-Line Phase 3 Data From Pivotal Firdapse Clinical Trial in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
GlobeNewswire - Mon Sep 29, 3:03PM CDT
Treatment with Firdapse achieved statistical significance for both co-primary clinical endpoints
CPRX: 2.97 (+0.23)
DON, EEB, PRFZ, CPRX, RGI, DVR Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Sep 10, 3:54AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Donner Metals Ltd (NYSE
ON), Guggenheim BRIC ETF (NYSE:EEB), PowerShares FTSE RAFI US 1500 Small-Mid Portfolio (NASDAQ RFZ), Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX), Reco International Group Inc (NYSE:RGI), Cal Dive International Inc (NYSE VR) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: DON: 81.83 (+0.85), RGI: 87.96 (+0.91), DVR: 0.14 (-0.08), CPRX: 2.97 (+0.23), RGI.VN: 0.015 (unch), PRFZ: 99.11 (+1.57), EEB: 34.47 (+0.32)
Opium (Opioid) Addiction - Pipeline Review, H2 2014 - 19 Drug Profiles from 13 Companies
M2 - Tue Sep 09, 6:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/76t4hq/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alkermes Plc - Nanotherapeutics, Inc. - Acura Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - INSYS Therapeutics, Inc. - Camurus AB - Omeros Corporation - D&A Pharma SAS - Reckitt Benckiser Pharmaceutical, Inc. - AllTranz, Inc. - Relmada Therapeutics, Inc. - Celtic Pharmaceutical Holdings L.P. - Foresee Pharmaceuticals, LLC Drug Profiles - TA-CD - buprenorphine hydrochloride - RBP-6300 - Cannabidiol - OMS-405 - MAL - samidorphan - (buprenorphine hydrochloride naloxone hydrochloride) - CPP-115 - OMS-527 - buprenorphine hydrochloride ER - Vaccine for Opium Addiction - Cannabidiol - FP-004 - methadone IR - buprenorphine hydrochloride - Synthetic Peptides to Activate DOR and MOR and Inhibit MRP-1 for Oncology and Morphine Addiction - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - naltrexone For more information visit http://www.researchandmarkets.com/research/76...ium_opioid
INSY: 40.67 (-1.32), CPRX: 2.97 (+0.23), ALKS: 50.55 (-0.74), ACUR: 0.61 (-0.02), OMER: 16.57 (unch)
Biotech Equities Technical Review -- Celldex Therapeutics, Synthetic Biologics, Geron, Catalyst Pharmaceutical Partners, and NPS Pharmaceuticals
PR Newswire - Mon Sep 08, 8:15AM CDT
On Friday, September 05, 2014, the NASDAQ Composite ended at 4,582.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.40% higher at 17,137.36, and the S&P 500 closed at 2,007.71, up 0.50%. The gains were broad based as all the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 741.23, up 0.57%, and the index has advanced 5.89% in the last one month. Investor-Edge has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Synthetic Biologics Inc. (NYSE MKT: SYN), Geron Corporation (NASDAQ: GERN), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX), and NPS Pharmaceuticals Inc. (NASDAQ: NPSP). Free research on these five companies can be accessed at:
SYN: 1.51 (-0.06), CPRX: 2.97 (+0.23), GERN: 2.23 (+0.02), CLDX: 16.75 (-0.27), NPSP: 27.40 (-1.06)
Catalyst Pharmaceutical (CPRX) Jumps: Stock Up 9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 7:51AM CDT
Catalyst Pharmaceutical Partners Inc. (CPRX) was a big mover last session, as its shares rose nearly 9% on the day.
LCI: 56.72 (+0.83), ENDP: 66.92 (+0.63), CPRX: 2.97 (+0.23), HPTX: 24.30 (-0.13)
Catalyst Pharmaceuticals hires David D. Muth as EVP of Corporate Development
M2 - Fri Sep 05, 6:32AM CDT
Biopharmaceutical company Catalyst Pharmaceutical Partners (NasdaqCM:CPRX) reported on Thursday the addition of David D. Muth as executive vice president of its Corporate Development.
CPRX: 2.97 (+0.23)
Catalyst Pharmaceuticals Appoints David D. Muth as Executive Vice President, Corporate Development
GlobeNewswire - Thu Sep 04, 7:26AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the appointment of David D. Muth to the newly created position, Executive Vice President, Corporate Development. Mr. Muth will report to Patrick McEnany, Chairman, President and Chief Executive Officer of Catalyst. As Executive Vice President, Corporate Development, Mr. Muth will be responsible for all of Catalyst's corporate development activities and will work closely with the other members of the Catalyst team in preparing a commercialization strategy for Firdapse(TM).
CPRX: 2.97 (+0.23)
Catalyst Pharmaceutical Partners to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
GlobeNewswire - Wed Sep 03, 7:08AM CDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will be presenting at Rodman & Renshaw's 16 Annual Global Investment Conference, which is being held on September 8-10, 2014 at The Palace Hotel in New York, NY.
CPRX: 2.97 (+0.23)
